Keitel-Anselmino, V., Kern, W.V., Ohmann, C. und RES-Q-HR Trial Team, S. group (2021) Reconvalescent plasma/camostat mesylate in early SARS-Co V-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial [cd]. Freiburg: Universität. doi:10.1186/s13063-021-05181-0.

Keitel-Anselmino, Verena, Winfried V. Kern, Christian Ohmann, und Study group RES-Q-HR Trial Team. Reconvalescent plasma/camostat mesylate in early SARS-Co V-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial. Cd. Freiburg: Universität, [2021?], Freiburg: Universität, [2021?]. https://doi.org/10.1186/s13063-021-05181-0.

Keitel-Anselmino, V., Kern, W. V., Ohmann, C., & RES-Q-HR Trial Team, S. group. (ca. 2021). Reconvalescent plasma/camostat mesylate in early SARS-Co V-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial [Cd]. Universität. https://doi.org/10.1186/s13063-021-05181-0

Keitel-Anselmino, V., W. V. Kern, C. Ohmann, und S. group RES-Q-HR Trial Team. Reconvalescent plasma/camostat mesylate in early SARS-Co V-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial. cd, Universität, 2021, https://doi.org/10.1186/s13063-021-05181-0.

KEITEL-ANSELMINO, Verena, Winfried V. KERN, Christian OHMANN und Study group RES-Q-HR TRIAL TEAM, 2021. Reconvalescent plasma/camostat mesylate in early SARS-Co V-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial. Freiburg: Universität